Salivary Gland Cancer - Pipeline Review, H2 2015

Published: December 2015
No. of Pages: 59
   

Global Markets Direct’s, ‘Salivary Gland Cancer - Pipeline Review, H2 2015’, provides an overview of the Salivary Gland Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Salivary Gland Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Salivary Gland Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Salivary Gland Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Salivary Gland Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Salivary Gland Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Salivary Gland Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Salivary Gland Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Salivary Gland Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Salivary Gland Cancer - Pipeline Review, H2 2015

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Salivary Gland Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Salivary Gland Cancer - Overview 7
Pipeline Products for Salivary Gland Cancer - Comparative Analysis 8
Salivary Gland Cancer - Therapeutics under Development by Companies 9
Salivary Gland Cancer - Therapeutics under Investigation by Universities/Institutes 10
Salivary Gland Cancer - Pipeline Products Glance 11
Clinical Stage Products 11
Salivary Gland Cancer - Products under Development by Companies 12
Salivary Gland Cancer - Products under Investigation by Universities/Institutes 13
Salivary Gland Cancer - Companies Involved in Therapeutics Development 14
AstraZeneca Plc 14
Bayer AG 15
Ignyta, Inc. 16
Loxo Oncology, Inc. 17
Otsuka Holdings Co., Ltd. 18
Plexxikon Inc. 19
Salivary Gland Cancer - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
AZD-5312 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Cellular Immunotherapy for Oncology - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
entrectinib - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
LOXO-101 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
OPB-111001 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
pexidartinib - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
regorafenib - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Salivary Gland Cancer - Recent Pipeline Updates 43
Salivary Gland Cancer - Dormant Projects 56
Salivary Gland Cancer - Discontinued Products 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

List of Tables

Number of Products under Development for Salivary Gland Cancer, H2 2015 7
Number of Products under Development for Salivary Gland Cancer - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Products under Development by Companies, H2 2015 12
Products under Investigation by Universities/Institutes, H2 2015 13
Salivary Gland Cancer - Pipeline by AstraZeneca Plc, H2 2015 14
Salivary Gland Cancer - Pipeline by Bayer AG, H2 2015 15
Salivary Gland Cancer - Pipeline by Ignyta, Inc., H2 2015 16
Salivary Gland Cancer - Pipeline by Loxo Oncology, Inc., H2 2015 17
Salivary Gland Cancer - Pipeline by Otsuka Holdings Co., Ltd., H2 2015 18
Salivary Gland Cancer - Pipeline by Plexxikon Inc., H2 2015 19
Assessment by Monotherapy Products, H2 2015 20
Number of Products by Stage and Target, H2 2015 22
Number of Products by Stage and Mechanism of Action, H2 2015 24
Number of Products by Stage and Route of Administration, H2 2015 26
Number of Products by Stage and Molecule Type, H2 2015 28
Salivary Gland Cancer Therapeutics - Recent Pipeline Updates, H2 2015 43
Salivary Gland Cancer - Dormant Projects, H2 2015 56
Salivary Gland Cancer - Discontinued Products, H2 2015 57

List of Figures

Number of Products under Development for Salivary Gland Cancer, H2 2015 7
Number of Products under Development for Salivary Gland Cancer - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 11
Assessment by Monotherapy Products, H2 2015 20
Number of Products by Top 10 Targets, H2 2015 21
Number of Products by Stage and Top 10 Targets, H2 2015 21
Number of Products by Top 10 Mechanism of Actions, H2 2015 23
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 23
Number of Products by Routes of Administration, H2 2015 25
Number of Products by Stage and Routes of Administration, H2 2015 25
Number of Products by Molecule Types, H2 2015 27
Number of Products by Stage and Molecule Types, H2 2015 27

Published By: Global Markets Direct
Product Code: Global Markets Direct14020


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we�ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: